Vasculitis Clinical Trial
Official title:
Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis
This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients
with Wegener's granulomatosis, a type of vasculitis (blood vessel inflammation). Wegener's
granulomatosis may affect many parts of the body, including the brain, nerves, eyes,
sinuses, lungs, kidneys, intestinal tract, skin, joints, heart, and other sites. Generally,
the greater the disease involvement, the more life-threatening it is. Standard treatment is
a combination of prednisone and a cytotoxic agent-usually cyclophosphamide or methotrexate.
However, many patients treated with this regimen have a disease relapse, and others cannot
take these drugs because of severe side effects. This study will evaluate etanercept's
safety and effectiveness, and particularly its value in reducing the need for prednisone and
preventing disease relapse.
The Food and Drug Administration has approved etanercept for treating rheumatoid arthritis,
another inflammatory disease. The drug works by blocking the activity of TNF-a protein made
by white blood cells that is involved in the inflammatory process. Since prednisone also
affects inflammatory proteins and lowers TNF production, the use of etanercept may reduce
the need for prednisone in patients with Wegener's granulomatosis, and thus the risk of its
side effects.
Patients between 10 and 70 years of age with Wegener's granulomatosis who have never taken
prednisone, methotrexate or cyclophosphamide, or have taken these drugs for less than 3
weeks may be eligible for this study.
Participants will have a medical history review and physical examination, including
laboratory studies. If medically indicated, X-rays, consultations and biopsies (surgical
removal of a small tissue sample) of affected organs will also be done. All patients will
begin treatment with prednisone, methotrexate and etanercept. Those who improve on this
regimen will stop prednisone gradually over 3 months. Those who achieve disease remission at
the end of another 3 months will be randomly assigned to either continue taking etanercept
and methotrexate for another 12 months or to stop etanercept and continue only methotrexate
for the next 12 months (after which methotrexate will gradually be stopped). Patients who
are not in remission by the 6-month point will continue taking etanercept until they go into
remission, when they will be assigned to stop or not stop etanercept, as described above.
Patients who do not achieve remission within 12 months of beginning treatment will be taken
off the study. Patients who have a disease relapse while on the study will likely be
switched to treatment with prednisone and either methotrexate or cyclophosphamide. Patients
randomized to stop etanercept and who have a relapse within a year of stopping the drug may
be offered re-treatment on this protocol, but with continuing etanercept for a full year
after remission.
Patients will be evaluated in the outpatient clinic every 2 to 4 weeks for the first 4
months and every 1 to 3 months after that. Patients whose disease is in remission and who
stop all medications will be followed every 3 to 6 months for 2 years. Follow-up evaluations
include a physical examination, blood draws and, if medically indicated, X-rays. The total
study duration is 60 to 70 months.
Status | Completed |
Enrollment | 60 |
Est. completion date | March 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Documentation of Wegener's granulomatosis based on clinical characteristics and histopathologic and/or angiographic evidence of vasculitis. In the absence of histopathologic and/or angiographic evidence of vasculitis, patients who meet one of the following criteria and in whom infectious and autoimmune diseases that may mimic Wegener's granulomatosis or a related systemic vasculitides have been excluded will also be eligible: a) a positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the presence of glomerulonephritis defined by red blood cell casts and proteinuria or renal biopsy showing necrotizing glomerulonephritis in the absence of immune deposits; b) a positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the presence of granulomatous inflammation on biopsy plus abnormal chest radiograph (defined as the presence of nodules, fixed infiltrates, or cavities) plus nasal/oral inflammation on clinical examination. Subjects must be between the ages of 10 - 70 years. Subject must have evidence of active major organ disease. Patients who have never been previously seen at the NIH will be eligible if the above conditions are met and they either: are not receiving treatment; have been receiving prednisone at induction doses and MTX for less than 3 weeks; have been receiving prednisone at induction doses and CYC for less than 3 weeks but did not have severe disease. EXCLUSION CRITERIA: Patients with evidence of bacterial sepsis. Patients with evidence of other active systemic infection which in the judgment of the investigator, is of greater danger to the patient than the underlying vasculitis. Pregnant or subjects who are nursing infants. Fertile women must have a negative pregnancy test within one week prior to study entry and all participants must be using effective means of birth control. Patients with one or more of the following: serum creatinine greater than 2.5 mg/dl or creatinine clearance less than 35 ml/min; pulmonary disease resulting in a pO(2) less than 70 mmHg, or FVC, FEV(1) or DLCO less than 70% of predicted; any Wegener's granulomatosis-related disease manifestation that, in the judgment of the investigators, is immediately life-threatening. Hemocytopenia: platelet count less than 80,000/mm(3), leukocyte count less than 3,000/mm(3), hematocrit less than 20% (in the absence of gastrointestinal bleeding or hemolytic anemia). Liver function test abnormalities greater than three times upper limits of normal (either serum GOT, GPT, alkaline phosphatase, and/or bilirubin). Processes associated with an increased risk of MTX toxicity: acute or chronic liver disease, past history of alcohol abuse (greater than 14 oz. of 100 proof liquor or equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon entry into the study. Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a positive hepatitis B surface antigen. A serological determination will be performed within two weeks of beginning study participation. Treatment with any investigational drug within 30 days. Known allergy to TNFR:Fc. Individuals with a history of psychiatric illness that in the opinion of the principal investigator (PI) would preclude entrance into the study. History of multiple sclerosis or other demyelinating disease. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76-85. Review. — View Citation
Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973 Nov;52(6):535-61. — View Citation
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Completed |
NCT01363388 -
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
|
Phase 2 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT01947465 -
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
|
N/A | |
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Completed |
NCT03693586 -
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
|
||
Completed |
NCT05604482 -
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
|
N/A | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05383339 -
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05565885 -
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
|
||
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Recruiting |
NCT02856243 -
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
|
N/A | |
Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
Active, not recruiting |
NCT03692416 -
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
|
Phase 3 | |
Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
Terminated |
NCT03937856 -
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
|
N/A |